A new tool for personalized immune assessment
Cellintec is developing an immune profile test, Methylation Cytometry(TM), that is uniquely positioned to easily and accurately track how a patient’s immune system is responding to disease and therapy. This ability to comprehensively monitor the changes in a patient’s immune system over the course of a disease and its treatment has the potential to be a game changer in healthcare.
Figure adapted from Salas et al. Nature Communications 2022
Measuring Immune Response to Cancer Therapy
Cancer immunotherapy, which harnesses the immune system to fight cancer, is one of the most powerful cancer therapies to be developed in decades. It can be very effective against cancers that have historically been resistant to chemotherapy and radiation and result in longer lasting remissions. But the response rate to immunotherapy is low—typically 25% or less. It can also be dangerous. If the immune system is over-activated, patients can experience potentially deadly autoimmune-related side effects.
The ability to closely monitor a patient’s immune system using Cellintec’s Methylation Cytometry test would enable clinicians to detect, early in the treatment cycle and throughout the course of therapy, whether a patient’s immune system has been activated enough to fight cancer or over activated, potentially leading to autoimmunity. This would allow clinicians to halt or modify therapy if a patient is not responding appropriately.
